subjects will be treated with HBM4003 in combination with pembrolizumab for up to 2 years or until confirmed disease progression, unacceptable tolerability or treatment discontinuation through withdrawal of consent occurs, whichever happens first.~This trial consists of :~A screening period: 28 days~A treatment period:~Part 1a dose confirmation study~Part 1b dose expansion study~A post-treatment follow-up period, including~A safety follow-up period: 28 days after the last dose of study drug;~Post-treatment follow-up visit: day 84 after the last dose of study drug;~Survival follow-up.
This is an open-label, multi-center phase 1 study. The trial, consisting of Part 1a dose confirmation and Part 1b dose expansion, is designed to evaluate the safety, tolerability, PK/PD and preliminary efficacy of HBM4003 in combination with pembrolizumab in patients with advanced NSCLC and other solid tumors.